Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has results × Adoptive Transfer × Clear all

Phase

Phase NA 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 119 pembrolizumab 98 Carboplatin 83 Nivolumab 81 Paclitaxel 76 Rituximab 72 Gemcitabine 68 Dexamethasone 67 Radiotherapy 60 Lenalidomide 58 Cytarabine 57 Cisplatin 55 Etoposide 52 Bevacizumab 52 fludarabine phosphate 49 Docetaxel 47 fludarabine 45 Bortezomib 43 Temozolomide 41 Erlotinib Hydrochloride 40 Doxorubicin 39 Prednisone 38 Capecitabine 38 Everolimus 37 Vorinostat 36 Sorafenib 36 Ipilimumab 36 Azacitidine 36 Melphalan 35 Filgrastim 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed

13 enrolled 12 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡